Compare SCOR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | NYXH |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 134.5M |
| IPO Year | 2007 | 2021 |
| Metric | SCOR | NYXH |
|---|---|---|
| Price | $6.45 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 9.7K | ★ 31.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | $213.98 |
| Revenue Next Year | $7.30 | $126.25 |
| P/E Ratio | $1.55 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $2.72 |
| 52 Week High | $10.18 | $8.59 |
| Indicator | SCOR | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 42.34 |
| Support Level | $6.22 | $2.80 |
| Resistance Level | $7.07 | $3.36 |
| Average True Range (ATR) | 0.38 | 0.16 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 20.38 | 22.22 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.